- Home
- ORIC vs PLRX Comparison
ORIC vs PLRX Comparison
Compare ORIC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- PLRX
- Stock Information
- Founded
- ORIC 2014
- PLRX 2015
- Country
- ORIC United States
- PLRX United States
- Employees
- ORIC N/A
- PLRX N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- PLRX Health Care
- Exchange
- ORIC Nasdaq
- PLRX Nasdaq
- Market Cap
- ORIC 362.9M
- PLRX 84.7M
- IPO Year
- ORIC 2020
- PLRX 2020
- Fundamental
- Price
- ORIC $10.50
- PLRX $1.29
- Analyst Decision
- ORIC Strong Buy
- PLRX Hold
- Analyst Count
- ORIC 8
- PLRX 10
- Target Price
- ORIC $18.83
- PLRX $9.79
- AVG Volume (30 Days)
- ORIC 1.1M
- PLRX 1.5M
- Earning Date
- ORIC 08-11-2025
- PLRX 08-06-2025
- Dividend Yield
- ORIC N/A
- PLRX N/A
- EPS Growth
- ORIC N/A
- PLRX N/A
- EPS
- ORIC N/A
- PLRX N/A
- Revenue
- ORIC N/A
- PLRX N/A
- Revenue This Year
- ORIC N/A
- PLRX N/A
- Revenue Next Year
- ORIC N/A
- PLRX N/A
- P/E Ratio
- ORIC N/A
- PLRX N/A
- Revenue Growth
- ORIC N/A
- PLRX N/A
- 52 Week Low
- ORIC $3.90
- PLRX $1.10
- 52 Week High
- ORIC $14.67
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- ORIC 70.83
- PLRX 38.40
- Support Level
- ORIC $9.80
- PLRX $1.13
- Resistance Level
- ORIC $11.19
- PLRX $1.43
- Average True Range (ATR)
- ORIC 0.61
- PLRX 0.11
- MACD
- ORIC -0.04
- PLRX -0.01
- Stochastic Oscillator
- ORIC 81.20
- PLRX 21.68
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.